-
Je něco špatně v tomto záznamu ?
Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines
J. Mašek, D. Lubasová, R. Lukáč, P. Turánek-Knotigová, P. Kulich, J. Plocková, E. Mašková, L. Procházka, Š. Koudelka, N. Sasithorn, J. Gombos, E. Bartheldyová, F. Hubatka, M. Raška, AD. Miller, J. Turánek,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV15-32198A
MZ0
CEP - Centrální evidence projektů
- MeSH
- adheziva chemie MeSH
- aplikace bukální MeSH
- aplikace sublinguální MeSH
- léčivé přípravky aplikace a dávkování MeSH
- lékové transportní systémy metody MeSH
- liposomy chemie MeSH
- lymfatické uzliny metabolismus MeSH
- myši MeSH
- nanočástice chemie MeSH
- nanovlákna chemie MeSH
- polyethylenglykoly chemie MeSH
- polyglactin 910 chemie MeSH
- prasata MeSH
- ústní sliznice metabolismus MeSH
- vakcinace metody MeSH
- vakcíny aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Nanofibre-based mucoadhesive films were invented for oromucosal administration of nanocarriers used for delivery of drugs and vaccines. The mucoadhesive film consists of an electrospun nanofibrous reservoir layer, a mucoadhesive film layer and a protective backing layer. The mucoadhesive layer is responsible for tight adhesion of the whole system to the oral mucosa after application. The electrospun nanofibrous reservoir layer is intended to act as a reservoir for polymeric and lipid-based nanoparticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus macromolecular drugs, antigens and/or allergens. The extremely large surface area of nanofibrous reservoir layers allows high levels of nanoparticle loading. Nanoparticles can either be reversibly adsorbed to the surface of nanofibres or they can be deposited in the pores between the nanofibres. After mucosal application, nanofibrous reservoir layers are intended to promote prolonged release of nanoparticles into the submucosal tissue. Reversible adsorption of model nanoparticles as well as sufficient mucoadhesive properties were demonstrated. This novel system appears appropriate for the use in oral mucosa, especially for sublingual and buccal tissues. To prove this concept, trans-/intramucosal and lymph-node delivery of PLGA-PEG nanoparticles was demonstrated in a porcine model. This system can mainly be used for sublingual immunization and the development of "printed vaccine technology".
Department of Immunology Palacky University Olomouc Czech Republic
Department of Pharmacology and Immunotherapy Veterinary Research Institute Brno Czech Republic
Institute of Pharmaceutical Science King's College London London United Kingdom
KP Therapeutics Ltd 86 Deansgate Manchester M3 2ER United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017133
- 003
- CZ-PrNML
- 005
- 20201109104554.0
- 007
- ta
- 008
- 180515s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2016.07.036 $2 doi
- 035 __
- $a (PubMed)27469472
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mašek, Josef $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic. Electronic address: masek@vri.cz.
- 245 10
- $a Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines / $c J. Mašek, D. Lubasová, R. Lukáč, P. Turánek-Knotigová, P. Kulich, J. Plocková, E. Mašková, L. Procházka, Š. Koudelka, N. Sasithorn, J. Gombos, E. Bartheldyová, F. Hubatka, M. Raška, AD. Miller, J. Turánek,
- 520 9_
- $a Nanofibre-based mucoadhesive films were invented for oromucosal administration of nanocarriers used for delivery of drugs and vaccines. The mucoadhesive film consists of an electrospun nanofibrous reservoir layer, a mucoadhesive film layer and a protective backing layer. The mucoadhesive layer is responsible for tight adhesion of the whole system to the oral mucosa after application. The electrospun nanofibrous reservoir layer is intended to act as a reservoir for polymeric and lipid-based nanoparticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus macromolecular drugs, antigens and/or allergens. The extremely large surface area of nanofibrous reservoir layers allows high levels of nanoparticle loading. Nanoparticles can either be reversibly adsorbed to the surface of nanofibres or they can be deposited in the pores between the nanofibres. After mucosal application, nanofibrous reservoir layers are intended to promote prolonged release of nanoparticles into the submucosal tissue. Reversible adsorption of model nanoparticles as well as sufficient mucoadhesive properties were demonstrated. This novel system appears appropriate for the use in oral mucosa, especially for sublingual and buccal tissues. To prove this concept, trans-/intramucosal and lymph-node delivery of PLGA-PEG nanoparticles was demonstrated in a porcine model. This system can mainly be used for sublingual immunization and the development of "printed vaccine technology".
- 650 _2
- $a adheziva $x chemie $7 D000269
- 650 _2
- $a aplikace bukální $7 D000278
- 650 _2
- $a aplikace sublinguální $7 D000286
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lékové transportní systémy $x metody $7 D016503
- 650 _2
- $a liposomy $x chemie $7 D008081
- 650 _2
- $a lymfatické uzliny $x metabolismus $7 D008198
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a ústní sliznice $x metabolismus $7 D009061
- 650 _2
- $a nanovlákna $x chemie $7 D057139
- 650 _2
- $a nanočástice $x chemie $7 D053758
- 650 _2
- $a léčivé přípravky $x aplikace a dávkování $7 D004364
- 650 _2
- $a polyethylenglykoly $x chemie $7 D011092
- 650 _2
- $a polyglactin 910 $x chemie $7 D011098
- 650 _2
- $a prasata $7 D013552
- 650 _2
- $a vakcinace $x metody $7 D014611
- 650 _2
- $a vakcíny $x aplikace a dávkování $7 D014612
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lubasová, Daniela $u Technical University of Liberec, Institute for Nanomaterials, Advanced Technologies and Innovation, Liberec, Czech Republic.
- 700 1_
- $a Lukáč, Róbert $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Turánek-Knötigová, Pavlína $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic. $7 xx0137875
- 700 1_
- $a Kulich, Pavel $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Plocková, Jana $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Mašková, Eliška $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic.
- 700 1_
- $a Procházka, Lubomír $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Koudelka, Štěpán $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Sasithorn, Nongnut $u Technical University of Liberec, Institute for Nanomaterials, Advanced Technologies and Innovation, Liberec, Czech Republic.
- 700 1_
- $a Gombos, Jozsef $u Leica Microsystems, Heerbrugg, Switzerland.
- 700 1_
- $a Bartheldyová, Eliška $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Hubatka, František $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Raška, Milan $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic; Department of Immunology, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Miller, Andrew D $u Institute of Pharmaceutical Science, King's College London, London, United Kingdom; KP Therapeutics Ltd, 86 Deansgate, Manchester, M3 2ER, United Kingdom.
- 700 1_
- $a Turánek, Jaroslav $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic. Electronic address: turanek@vri.cz.
- 773 0_
- $w MED00002621 $t Journal of controlled release official journal of the Controlled Release Society $x 1873-4995 $g Roč. 249, č. - (2017), s. 183-195
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27469472 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20201109104554 $b ABA008
- 999 __
- $a ok $b bmc $g 1300757 $s 1013973
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 249 $c - $d 183-195 $e 20160725 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- GRA __
- $a NV15-32198A $p MZ0
- LZP __
- $a Pubmed-20180515
